NeurAxis, Inc. announced on January 8, 2025, preliminary, unaudited revenues for the fourth quarter ended December 31, 2024. The company reported an approximate 50% increase in revenues for 4Q24 compared to the fourth quarter of 2023.
This preliminary report indicates continued strong commercial momentum for NeurAxis's neuromodulation therapies. The substantial year-over-year revenue growth suggests increasing adoption of its products in the market.
Additionally, the company reported a cash balance of approximately $3.7 million as of December 31, 2024. This cash position provides liquidity to support ongoing operations and strategic initiatives as NeurAxis continues to expand its market presence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.